French early nationwide idecabtagene ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.
Author(s) :
Ferment, B. [Auteur]
Université Paris Cité [UPCité]
Lambert, J. [Auteur]
Université Paris Cité [UPCité]
Caillot, D. [Auteur]
Institut de Cancérologie de Bourgogne
Lafon, I. [Auteur]
Institut de Cancérologie de Bourgogne
Karlin, L. [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Lazareth, A. [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Touzeau, C. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Leleu, X. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Moya, N. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Harel, S. [Auteur]
Université Paris Cité [UPCité]
Perrot, A. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Bories, P. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Vincent, L. [Auteur]
CHU Montpellier = Montpellier University Hospital
Lamure, S. [Auteur]
Centre Léon Bérard [Lyon]
Mohty, M. [Auteur]
Sorbonne Université [SU]
Malard, F. [Auteur]
Sorbonne Université [SU]
Manier, Salomon [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Schiano De Colella, J. M. [Auteur]
Institut Paoli-Calmettes [IPC]
Brisou, G. [Auteur]
Institut Paoli-Calmettes [IPC]
Talbot, A. [Auteur]
Université Paris Cité [UPCité]
Decaux, O. [Auteur]
Centre Hospitalier Universitaire [Rennes]
Houot, R. [Auteur]
Centre Hospitalier Universitaire [Rennes]
Le Gouill, S. [Auteur]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Bigot, N. [Auteur]
Université Paris Cité [UPCité]
Facon, Thierry [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Corre, J. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Moreau, P. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Arnulf, B. [Auteur]
Université Paris Cité [UPCité]
Université Paris Cité [UPCité]
Lambert, J. [Auteur]
Université Paris Cité [UPCité]
Caillot, D. [Auteur]
Institut de Cancérologie de Bourgogne
Lafon, I. [Auteur]
Institut de Cancérologie de Bourgogne
Karlin, L. [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Lazareth, A. [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Touzeau, C. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Leleu, X. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Moya, N. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Harel, S. [Auteur]
Université Paris Cité [UPCité]
Perrot, A. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Bories, P. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Vincent, L. [Auteur]
CHU Montpellier = Montpellier University Hospital
Lamure, S. [Auteur]
Centre Léon Bérard [Lyon]
Mohty, M. [Auteur]
Sorbonne Université [SU]
Malard, F. [Auteur]
Sorbonne Université [SU]
Manier, Salomon [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Yakoub-Agha, Ibrahim [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Schiano De Colella, J. M. [Auteur]
Institut Paoli-Calmettes [IPC]
Brisou, G. [Auteur]
Institut Paoli-Calmettes [IPC]
Talbot, A. [Auteur]
Université Paris Cité [UPCité]
Decaux, O. [Auteur]
Centre Hospitalier Universitaire [Rennes]
Houot, R. [Auteur]
Centre Hospitalier Universitaire [Rennes]
Le Gouill, S. [Auteur]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Bigot, N. [Auteur]
Université Paris Cité [UPCité]
Facon, Thierry [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Corre, J. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Moreau, P. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Arnulf, B. [Auteur]
Université Paris Cité [UPCité]
Journal title :
British Journal of Haematology
Abbreviated title :
Br J Haematol
Publication date :
2024-05-15
ISSN :
1365-2141
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory ...
Show more >Idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory multiple myeloma (RRMM). We conducted a real-world registry-based multicentre observational study in 11 French hospitals to evaluate ide-cel outcomes. Data from 176 RRMM patients who underwent apheresis between June 2021 and November 2022 were collected from the French national DESCAR-T registry. Of these, 159 patients (90%) received ide-cel. Cytokine release syndrome occurred in 90% with 2% grade ≥3, and neurotoxicity occurred in 12% with 3% grade ≥3. Over the first 6 months, the best overall response and ≥complete response rates were 88% and 47% respectively. The median progression-free survival (PFS) from the ide-cel infusion was 12.5 months, the median overall survival (OS) was 20.8 months and the estimated OS rate at 12 months was 73.3%. Patients with extra-medullary disease (EMD) had impaired PFS (6.2 months vs. 14.8 months). On multivariable analysis, EMD and previous exposure to BCMA-targeted immunoconjugate or T-cell-redirecting GPRC5D bispecific antibody were associated with inferior PFS. Our study supports ide-cel's feasibility, safety and efficacy in real-life settings, emphasizing the importance of screening for EMD and considering prior treatments to optimize patient selection.Show less >
Show more >Idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory multiple myeloma (RRMM). We conducted a real-world registry-based multicentre observational study in 11 French hospitals to evaluate ide-cel outcomes. Data from 176 RRMM patients who underwent apheresis between June 2021 and November 2022 were collected from the French national DESCAR-T registry. Of these, 159 patients (90%) received ide-cel. Cytokine release syndrome occurred in 90% with 2% grade ≥3, and neurotoxicity occurred in 12% with 3% grade ≥3. Over the first 6 months, the best overall response and ≥complete response rates were 88% and 47% respectively. The median progression-free survival (PFS) from the ide-cel infusion was 12.5 months, the median overall survival (OS) was 20.8 months and the estimated OS rate at 12 months was 73.3%. Patients with extra-medullary disease (EMD) had impaired PFS (6.2 months vs. 14.8 months). On multivariable analysis, EMD and previous exposure to BCMA-targeted immunoconjugate or T-cell-redirecting GPRC5D bispecific antibody were associated with inferior PFS. Our study supports ide-cel's feasibility, safety and efficacy in real-life settings, emphasizing the importance of screening for EMD and considering prior treatments to optimize patient selection.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-06-01T21:01:12Z
2024-08-21T09:41:05Z
2024-08-21T09:41:05Z
Files
- Br J Haematol - 2024 - Ferment - French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy.pdf
- Non spécifié
- Open access
- Access the document